Middle Meatal Bacteriology During Acute Respiratory Infection in Children
Information source: Oulu University Hospital
Information obtained from ClinicalTrials.gov on February 07, 2013 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Acute Respiratory Infection; Sinusitis
Intervention: placebo (Drug); amoxicillin clavulanate acid (Drug)
Phase: Phase 4
Status: Not yet recruiting
Sponsored by: Oulu University Hospital Official(s) and/or principal investigator(s): Jukka-Pekka Kuusiniemi, MD, Principal Investigator, Affiliation: Dept of Otolaryngology, Seinäjoki Central Hospital, Finland Eeva Löfgren, MD, Principal Investigator, Affiliation: Dept of Otolaryngology, Kokkola Central Hospital, Finland Anna Marttila, MD, Principal Investigator, Affiliation: Dept of Otolaryngology, University of Oulu, Finland Olli-Pekka Alho, professor, Study Director, Affiliation: Dept of Otolaryngology, University of Oulu, Finland Aila Kristo, MD, Study Director, Affiliation: Dept of Otolaryngology, University of Oulu, Finland Ulla Lantto, MD, Principal Investigator, Affiliation: Dept of Otolaryngology, University of Oulu, Finland
Overall contact: Aila A Kristo, MD, Phone: +35883153492, Email: aila.kristo@ppshp.fi
Summary
The purpose of this study is to find out whether the children with respiratory infection and
the presence of pathogenic bacteria (S. pneumoniae, H. influenzae or M. catarrhalis) in the
nasal middle meatus benefit from antimicrobial treatment.
Clinical Details
Official title: Clinical Relevance of Middle Meatal Bacteriology During Acute Respiratory Infection in Children - Randomised, Double-Blinded Clinical Study
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Duration of continuous daily symptoms of the acute respiratory infection diagnosed at the study entry.
Secondary outcome: duration (days)and severity (grade mild, severe) of different symptoms (clear nasal discharge, coloured nasal discharge, nasal obstruction, cough, throat pain, ear ache, fever, headache, diarrhea)number of days the child is using the following symptomatic drugs (pain killers, nasal vasoconstrictors, nasal corticosteroids, asthma drugs, antihistamines) number of days the child is not at school and that the parents are not at work
Detailed description:
Acute sinusitis is one of the most common disease in children requiring antimicrobial
treatment. The diagnosis and treatment outcomes of acute sinusitis are contradictory, and
better diagnostic criteria are needed. In adults with acute maxillary sinusitis, bacterial
culture results obtained from the nasal middle meatus are comparable to those obtained from
sinus puncture and aspiration. In children, the presence of pathogenic bacteria (S.
pneumoniae, H. influenzae or M. catarrhalis) in the nasal middle meatus during respiratory
infection predicts longer duration of signs and symptoms of common cold.
In this randomized placebo-controlled study, the effect of the antimicrobial treatment
(amoxicillin-clavulanate) is examined in children with pathogenic bacteria (S. pneumoniae,
H. influenzae or M. catarrhalis) in the nasal middle meatus during respiratory infection.
The duration of the symptoms and speed of recovery is recognized by daily symptom-diary, the
results are compared between the treatment groups.
Eligibility
Minimum age: 6 Years.
Maximum age: 13 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- acute respiratory infection with nasal symptoms (nasal obstruction or discharge)
- seeking medical help from health centre for the respiratory symptoms
- pathogenic bacteria (S pneumoniae, H influenzae or M catarrhalis) identified from
right or left nasal middle meatus in the endoscopically taken swab culture sampling
taken by a study investigator (all microbiological analyses are done by the National
Public Health Institute´s microbiological laboratory in Oulu)
Exclusion Criteria:
- otitis, tonsillitis or other disease requiring antimicrobial treatment
- respiratory infection within 4 weeks of screening
- antimicrobial treatment within 4 weeks of screening
- allergy to penicillin or amoxicillin
Locations and Contacts
Aila A Kristo, MD, Phone: +35883153492, Email: aila.kristo@ppshp.fi
Keski-pohjanmaan keskussairaala, Kokkola, Finland; Not yet recruiting Eeva Löfgren, MD, Sub-Investigator
Oulu University Hospital, Oulu, Finland; Not yet recruiting Aila Kristo, MD, Principal Investigator Anna Marttila, MD, Sub-Investigator Ulla Lantto, MD, Sub-Investigator
Etelä-Pohjanmaan Keskussairaala, Seinäjoki, Finland; Not yet recruiting Jukka-Pekka Kuusiniemi, MD, Sub-Investigator
Additional Information
Starting date: November 2007
Last updated: October 18, 2007
|